EP0994717A4 - TREATING AUTOIMMUNE DISEASES BY TOLERANCE INCREASED BY COMBINING WITH METHOTREXATE - Google Patents
TREATING AUTOIMMUNE DISEASES BY TOLERANCE INCREASED BY COMBINING WITH METHOTREXATEInfo
- Publication number
- EP0994717A4 EP0994717A4 EP98908452A EP98908452A EP0994717A4 EP 0994717 A4 EP0994717 A4 EP 0994717A4 EP 98908452 A EP98908452 A EP 98908452A EP 98908452 A EP98908452 A EP 98908452A EP 0994717 A4 EP0994717 A4 EP 0994717A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tolerization
- methotrexate
- treatment
- combination
- autoimmune disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US36722P | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0994717A1 EP0994717A1 (en) | 2000-04-26 |
EP0994717A4 true EP0994717A4 (en) | 2000-07-26 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98908452A Withdrawn EP0994717A4 (en) | 1997-01-24 | 1998-01-26 | TREATING AUTOIMMUNE DISEASES BY TOLERANCE INCREASED BY COMBINING WITH METHOTREXATE |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (ja) |
JP (1) | JP2001511134A (ja) |
KR (1) | KR20000070460A (ja) |
AU (1) | AU6648898A (ja) |
BR (1) | BR9807112A (ja) |
CA (1) | CA2278152A1 (ja) |
HU (1) | HUP0001960A2 (ja) |
IL (1) | IL131025A0 (ja) |
NO (1) | NO993600L (ja) |
WO (1) | WO1998032451A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE409057T1 (de) | 2002-02-11 | 2008-10-15 | Antares Pharma Inc | Intradermales injektionsgerät |
WO2006079064A1 (en) | 2005-01-24 | 2006-07-27 | Antares Pharma, Inc. | Prefilled needle assisted jet injector |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2009114542A1 (en) | 2008-03-10 | 2009-09-17 | Antares Pharma, Inc. | Injector safety device |
ES2738539T3 (es) | 2008-08-05 | 2020-01-23 | Antares Pharma Inc | Inyector de dosis múltiples |
CA2755779C (en) | 2009-03-20 | 2015-11-10 | Antares Pharma, Inc. | Hazardous agent injection system |
EP2799071B1 (en) | 2010-06-16 | 2018-10-17 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast for the treatment of influenza and common cold |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
FI2822618T3 (fi) | 2012-03-06 | 2024-03-21 | Antares Pharma Inc | Esitäytetty injektioruisku laukeamisvoimaominaisuuden kera |
KR20150011346A (ko) | 2012-04-06 | 2015-01-30 | 안타레스 팔마, 인코퍼레이티드 | 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법 |
WO2013169800A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
FI3659647T3 (fi) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima |
WO2014164786A1 (en) | 2013-03-11 | 2014-10-09 | Madsen Patrick | Dosage injector with pinion system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
JP2016512262A (ja) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 |
ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
EP3300734B1 (en) | 2013-03-13 | 2019-08-14 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992004049A1 (en) * | 1990-09-06 | 1992-03-19 | Rijksuniversiteit Te Utrecht | Inhibitor of lymphocyte response and immune-related disease |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
EP0666080A1 (en) * | 1987-06-24 | 1995-08-09 | Brigham & Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
WO1996041644A1 (fr) * | 1995-06-13 | 1996-12-27 | Nippon Meat Packers, Inc. | Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
-
1998
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/en not_active Withdrawn
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/en not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/en not_active Abandoned
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666080A1 (en) * | 1987-06-24 | 1995-08-09 | Brigham & Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
WO1992004049A1 (en) * | 1990-09-06 | 1992-03-19 | Rijksuniversiteit Te Utrecht | Inhibitor of lymphocyte response and immune-related disease |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
WO1996041644A1 (fr) * | 1995-06-13 | 1996-12-27 | Nippon Meat Packers, Inc. | Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif |
Non-Patent Citations (2)
Title |
---|
AL-SABBAGH, A.M., ET AL.: "Combination of oral antigens with oral methotrexate enhances suppression of autoimmune disease", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1(PART 2), Abs. 99, January 1997 (1997-01-01), pages s24, XP000909440 * |
See also references of WO9832451A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2278152A1 (en) | 1998-07-30 |
IL131025A0 (en) | 2001-01-28 |
JP2001511134A (ja) | 2001-08-07 |
HUP0001960A2 (hu) | 2000-10-28 |
AU6648898A (en) | 1998-08-18 |
NO993600L (no) | 1999-09-23 |
KR20000070460A (ko) | 2000-11-25 |
BR9807112A (pt) | 2001-09-18 |
NO993600D0 (no) | 1999-07-23 |
WO1998032451A1 (en) | 1998-07-30 |
EP0994717A1 (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131025A0 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
ZA989461B (en) | Methods and compositions for the treatment of autoimmune disease using heat shock proteins | |
ZA9710339B (en) | Xanthines and their therapeutic use | |
HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
ZA983452B (en) | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. | |
IL159785A0 (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
EP0924983A4 (en) | S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | |
EP0966386A4 (en) | HUMAN TRACTION VEHICLE | |
PL344451A1 (en) | Use of cyclosporins in the treatment of inflammatory autoimmune diseases | |
HUP0001276A2 (en) | Illuminating body for swimming pools and similar | |
ZA984174B (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases | |
IL113303A0 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
HU9602751D0 (en) | Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
GB9419553D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
HK1025954A1 (en) | Triptolide derivatives useful in the treatment of autoimmune diseases | |
EP0797440A4 (en) | TREATING AUTOIMMUNE DISEASES WITH THE AID OF 2-AMINOPURINE DERIVATIVES | |
GB9621825D0 (en) | Microparticles and their use as therapeutic vehicles | |
GB9705200D0 (en) | Well treatment with particles | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
EP1073459A4 (en) | COMPOSITIONS AND METHODS OF TOLERATING IN IMMUNOMOPLEX-MEDIATED ILLNESS | |
AU7262800A (en) | Diagnostic and therapeutic methods in autoimmune disease | |
EP1020517A4 (en) | A HUMAN CHONDROCYTE GENE | |
IL132845A0 (en) | Non-myeloablative tolerogenic treatment | |
GB9706857D0 (en) | Car boot seat and table |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990818 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000614 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/505 A, 7A 61K 39/00 B, 7A 61P 37/00 B, 7A 61K 39/00 J, 7A 61K 31:505 J |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000801 |